Condition

Mantle Cell Lymphoma clinical trials and research

• 66Clinical trials
• 13NIH research projects
• 26Countries

Newest Mantle Cell Lymphoma clinical trials

All recruiting trials (66)

• Glofitamab for mantle cell lymphoma after CAR-T failure

  This phase 2, multicenter, single-arm study tests glofitamab in adults with mantle cell lymphoma who did not respond to or relapsed after CAR-T cell therapy.

  Recruiting Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria and 13 other locations · NCT07453095

• Rocbrutinib versus other BTK inhibitors for relapsed or refractory mantle cell lymphoma

  This trial tests whether rocbrutinib works better than other BTK inhibitors for people with mantle cell lymphoma that returned or didn't respond after at least one prior treatment and who have not previously received a BTK inhibitor (except for intolerance).

  Recruiting Phase 3 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality and 1 other locations · NCT07377578

• Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

  This trial tests whether adding two oral drugs, sonrotoclax and zanubrutinib, to standard CAR-T therapy helps people with mantle cell lymphoma who have relapsed or are refractory after prior treatment.

  Recruiting at 5 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 4 other locations · NCT07341191

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Obinutuzumab plus zanubrutinib and lenalidomide as first treatment for mantle cell lymphoma

  This trial will test whether a combination of obinutuzumab, zanubrutinib, and lenalidomide (with CAR‑T offered for high‑risk patients) works as a first‑line option for people newly diagnosed with mantle cell lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07261163

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Acalabrutinib plus R-CHOP as first-line treatment for mantle cell lymphoma in Spain

  This test will see if adding acalabrutinib to standard R-CHOP helps adults in Spain with newly diagnosed mantle cell lymphoma.

  Recruiting at 21 sites Phase 2 AstraZeneca · A Coruña and 21 other locations · NCT07029737

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• ImmunoPET imaging for detecting malignant cancers

  This study is testing a new imaging method to see if it can better detect certain types of cancer in patients who have or might have these diseases.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT06852638

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Comparing sonrotoclax plus zanubrutinib to placebo plus zanubrutinib for relapsed mantle cell lymphoma

  This study is testing if adding sonrotoclax to zanubrutinib can help adults with relapsed mantle cell lymphoma feel better compared to just taking zanubrutinib with a placebo.

  Recruiting at 95 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 144 other locations · NCT06742996

• Investigating a new dosing schedule for sonrotoclax in blood cancer treatment

  This study is testing new ways to give the drug sonrotoclax to see if it can safely help people with chronic lymphocytic leukemia (CLL) feel better.

  Recruiting at 22 sites Phase 1/2 BeOne Medicines · Tampa, Florida and 21 other locations · NCT06697184

• Combining nemtabrutinib and rituximab to treat mantle cell lymphoma

  This study is testing if combining two treatments, nemtabrutinib and rituximab, can help people with newly diagnosed mantle cell lymphoma feel better and live longer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06572618

• Evaluating AZD0486 for treating mature B-cell cancers

  This study is testing a new treatment called AZD0486 to see if it can help people with certain types of mature B-cell cancers feel better and improve their health.

  Recruiting at 56 sites Phase 1/2 AstraZeneca · Boston, Massachusetts and 65 other locations · NCT06564038

• Combination of Pirtobrutinib and Brexucabtagene Autoleucel for Relapsed Mantle Cell Lymphoma

  This study is testing if combining two treatments, Pirtobrutinib and Brexucabtagene Autoleucel, can help people with relapsed mantle cell lymphoma feel better and improve their outcomes.

  Recruiting at 2 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Stanford, California and 2 other locations · NCT06553872

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• CAR-T-cell treatment for high-risk mantle cell lymphoma

  This study is testing a new CAR-T-cell treatment for high-risk mantle cell lymphoma to see if it works better than standard therapies for younger and healthier elderly patients.

  Recruiting at 2 sites Phase 2 Ludwig-Maximilians - University of Munich · Mainz and 1 other locations · NCT06482684

• Comparing Orelabrutinib with standard treatment for mantle cell lymphoma

  This study is testing if adding a new drug called Orelabrutinib to the standard treatment can help older patients with untreated mantle cell lymphoma feel better and improve their outcomes.

  Recruiting at 19 sites Phase 3 InnoCare Pharma Inc. · Beijing and 38 other locations · NCT06363994

• Glofitamab plus ibrutinib and obinutuzumab for mantle cell lymphoma

  This trial will see if combining glofitamab with ibrutinib and obinutuzumab is safe and effective for adults with previously untreated, high‑risk or age‑65‑and‑older mantle cell lymphoma.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06357676

• Using Zanubrutinib to maintain remission in patients with Mantle Cell Lymphoma

  This study is testing if Zanubrutinib can help people with mantle cell lymphoma stay in remission after their initial treatment.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06341556

• Using CAR T cells to treat certain types of B cell lymphomas

  This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06340737

• Observational study on CAR-T therapy for lymphoma in Italy

  This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06339255

• Combination treatment for low and intermediate risk Mantle Cell Lymphoma

  This study is testing a new combination of two drugs, pirtobrutinib and rituximab, to see if it can effectively treat people with low and intermediate risk Mantle Cell Lymphoma without using chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06263491

• Combining glofitamab and pirtobrutinib for treating relapsed or refractory mantle cell lymphoma

  This study is testing if combining two drugs, glofitamab and pirtobrutinib, can help people with relapsed or refractory mantle cell lymphoma feel better and live longer.

  Recruiting at 4 sites Phase 2 University of California, San Francisco · Davis, California and 3 other locations · NCT06252675

• Seeing CXCR4 in lymphoma and leukemia with a new PET tracer

  This study tests a new PET tracer called 18F-BL40 to see if it can image CXCR4-expressing cancers and compares it with the standard 18F-FDG in adults with various blood cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06224309

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Evaluating blood pressure management in patients with B-cell cancers on specific treatments

  This study is trying to see how blood pressure changes in people with B-cell cancers who are being treated with a specific type of medication, and what the best ways are to manage any high blood pressure they might develop.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151730

• Combination therapy for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with mantle cell lymphoma that hasn't responded to previous treatments.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06054776

• Combining Zanubrutinib and Tafasitamab for Mantle Cell Lymphoma

  This study is testing the best dose of a new combination treatment with Zanubrutinib and Tafasitamab to see if it helps people with mantle cell lymphoma manage their disease better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT06029309

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Comparing continuous and intermittent treatment with zanubrutinib for older patients with mantle cell lymphoma

  This study tests whether older patients with mantle cell lymphoma do better with continuous or intermittent treatment using zanubrutinib after they have achieved complete remission with rituximab.

  Recruiting at 233 sites Phase 3 Alliance for Clinical Trials in Oncology · Little Rock, Arkansas and 241 other locations · NCT05976763

• Combining stem cell collection with CAR T-cell therapy for blood cancers

  This study is testing if collecting stem cells from patients with blood cancers can safely be combined with CAR T-cell therapy to improve treatment outcomes.

  Recruiting Phase 1 Cedars-Sinai Medical Center · Los Angeles, California · NCT05887167

• Treatment for relapsed mantle cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with relapsed mantle cell lymphoma who haven't had success with other treatments.

  Recruiting Phase 2 Medical University of Vienna · Vienna · NCT05868395

• Combination treatment for newly diagnosed high-risk mantle cell lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed high-risk mantle cell lymphoma to see if it helps them live longer without the disease getting worse.

  Recruiting at 3 sites Phase 1/2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT05861050

• Combining Glofitamab and Pirtobrutinib for Mantle Cell Lymphoma

  This study is testing if combining two drugs, Glofitamab and Pirtobrutinib, can help people with relapsed or hard-to-treat Mantle Cell Lymphoma feel better and possibly achieve complete remission.

  Recruiting at 2 sites Phase 2 Australasian Leukaemia and Lymphoma Group · Parkville, Victoria and 1 other locations · NCT05833763

• Observing heart rhythms in patients treated with BTK inhibitors or venetoclax

  This study is testing how Bruton’s tyrosine kinase inhibitors affect heart rhythms in people with chronic lymphocytic leukemia and comparing it to those taking venetoclax to see if there are any risks.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05724121

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Combining Zanubrutinib and Rituximab for Indolent Mantle Cell Lymphoma

  This study is testing if a new combination of two medications, zanubrutinib and rituximab, can help people with indolent mantle cell lymphoma who haven't been treated before.

  Recruiting at 13 sites Phase 2 University College, London · Derby and 12 other locations · NCT05635162

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Combining pirtobrutinib and venetoclax for treating relapsed mantle cell lymphoma

  This study is testing if combining two medications, pirtobrutinib and venetoclax, can help people with relapsed mantle cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05529069

• Using genetically modified T-cells and a vaccine to treat certain types of B-cell lymphoma after stem cell transplantation

  This study is testing a new treatment using specially modified immune cells and a vaccine to see if it can help people with certain types of B-cell lymphoma after they've had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05432635

• IKS03 treatment for advanced B cell non-Hodgkin lymphomas

  This study is testing a new treatment called IKS03 for people with advanced B cell non-Hodgkin lymphoma to see how safe and effective it is.

  Recruiting at 12 sites Phase 1 Iksuda Therapeutics Ltd. · Baltimore, Maryland and 12 other locations · NCT05365659

• Treatment for B-cell malignancies using BGB-16673

  This study is testing a new drug called BGB-16673 to see if it can safely help people with different types of B-cell cancers.

  Recruiting at 29 sites Phase 1/2 BeOne Medicines · Bengbu, Anhui and 28 other locations · NCT05294731

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Assessing ctDNA for monitoring lymphoma patients receiving CAR therapy

  This study is testing if measuring tumor DNA in the blood can help doctors keep track of lymphoma patients receiving CAR therapy and see if their cancer is coming back sooner than traditional scans.

  Recruiting Adaptive Biotechnologies · Palo Alto, California · NCT05255354

• Comparing two treatment regimens for elderly patients with mantle cell lymphoma

  This study is testing if an alternating treatment plan for mantle cell lymphoma can help older patients feel better compared to the standard treatment they usually receive.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gangnam-Gu · NCT05245656

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas

  This study is testing if combining two treatments, acalabrutinib and obinutuzumab, can help people with untreated follicular lymphoma and other slow-growing non-Hodgkin lymphomas feel better and improve their quality of life.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT04883437

• Combination treatment for mantle cell lymphoma

  This study is testing a combination of three drugs to see if they can help people with mantle cell lymphoma that has come back or hasn't been treated yet.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Chicago, Illinois and 2 other locations · NCT04855695

• Oral treatment with LP-168 for patients with certain blood cancers

  This study is testing an oral treatment called LP-168 to see if it can help adults with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 4 sites Phase 1 Newave Pharmaceutical Inc · Durham, North Carolina and 3 other locations · NCT04775745

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Using MRI-guided radiation therapy for treating certain cancers

  This study is testing if using MRI to guide radiation therapy along with chemotherapy can safely and effectively treat patients with gastric and breast cancers.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT04368702

• Treatment using modified T cells for certain types of lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with certain types of lymphoma that haven't responded to other therapies.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT04223765

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• Combination treatment for untreated Mantle Cell Lymphoma

  This study is testing a new combination of three drugs to see if it can help adults with untreated Mantle Cell Lymphoma feel better and respond well compared to standard treatments.

  Recruiting at 3 sites Phase 1/2 City of Hope Medical Center · Duarte, California and 3 other locations · NCT03523975

• Evaluating immune responses to influenza vaccination in lymphoma patients

  This study is testing how well the flu vaccine works for people with lymphoma by checking their immune responses after getting vaccinated.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT03501576

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Long-term follow-up of patients receiving CAR-T cell therapy

  This study is tracking patients who have received CAR-T cell therapy for up to 15 years to see how well the treatment works over time and if there are any long-term health issues.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT03375619

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

NIH-funded research (13)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies

  A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11451705

• Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients

  A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.

  NIH research Washington University · Saint Louis, United States · NIH-11374443

• ERBB signaling and ibrutinib resistance in mantle cell lymphoma

  A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11369418

• Why some mantle cell lymphomas respond to Notch-blocking drugs

  Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11306635

• Preventing a serious side effect of CAR T-cell therapy for lymphoma

  This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.

  NIH research Washington University · Saint Louis, United States · NIH-11166414

• Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments

  This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11127607

• Understanding how certain cancers respond to Notch inhibitors

  This study is looking into why some people with mantle cell lymphoma and chronic lymphocytic leukemia benefit from Notch inhibitors while others don’t, hoping to find clues in their genes that could help create better treatments for everyone.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11082432

• Investigating the role of specific proteins in mantle cell lymphoma

  This study is looking into how a specific protein called UBR5 affects the growth of mantle cell lymphoma, a rare type of blood cancer, to find new ways to help patients with this condition.

  NIH research University of Utah · Salt Lake City, United States · NIH-11063058

• Finding ways to overcome resistance to ibrutinib in mantle cell lymphoma

  This study is looking at why some people with mantle cell lymphoma stop responding to the drug ibrutinib, focusing on a protein called NFκB, to find ways to help those who aren't getting better with current treatments.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11017849

• Understanding how CEACAM1 affects B-cell signaling and treatment in mantle cell lymphoma

  This study is looking at a protein called CEACAM1 that might affect how certain immune cells work in people with mantle cell lymphoma, especially those who aren't responding well to treatments like ibrutinib, to find new ways to help improve their treatment options.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-10880440

• Investigating the role of SOX11 in aggressive B-cell lymphoma

  This study is looking at how a protein called SOX11 affects the growth of Mantle Cell Lymphoma, a serious type of blood cancer, using special mouse models to help find new ways to treat patients like you.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10854812

• Identifying how metabolic changes in mantle cell lymphoma respond to a specific cancer treatment.

  This study is looking at new, gentle ways to see how well treatments for mantle cell lymphoma are working by checking changes in the tumor's metabolism, which could help doctors make quicker decisions about your care.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10792594

• Targeting the mechanisms of drug resistance in mantle cell lymphoma

  This study is looking at why mantle cell lymphoma sometimes stops responding to treatment, and it's for patients who want to help researchers find better ways to fight this cancer by testing a new drug alongside current therapies.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-10478980

Related topics

Quick answers

How many Mantle Cell Lymphoma clinical trials are recruiting right now?

66, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (48 trials), China (10 trials), Australia (8 trials), Italy (7 trials), Spain (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 24, Phase 1: 15, Phase 1/2: 13, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →